Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027
Ashland reported Q4 FY2026 sales of $498 million, up 4% year-over-year, but swung to a GAAP loss from continuing operations of $17 million, or ($0.36) per diluted share, versus $0.73 a year earlier. Adjusted results were stronger: adjusted EPS excluding intangibles amortization was $1.12 (vs $1.08), adjusted EBITDA rose 2% to $121 million, and Ongoing Free Cash Flow improved to $74 million from $52 million. Life Sciences EBITDA jumped 16% to a record 35.6% margin, while Specialty Additives EBITDA fell 31% on Hopewell productivity issues.
Key figures
- Revenue
- 498000000
- Guidance
- FY2027 sales $1,905-$1,975 million (up ~2-6%) and Adjusted EBITDA $405-$435 million; Ongoing FCF conversion >40% of Adjusted EBITDA, capex up to ~$140 million
- Revenue Yoy
- 4%
- Cash
- 480000000
- Net debt
- 891000000
- Net leverage
- 2.3x
- Fy2026 revenue
- 1863000000
- Ongoing fcf q4
- 74000000
- Total liquidity
- 976000000
- Adjusted ebitda q4
- 121000000
- Fy2026 ongoing fcf
- 232000000
- Fy2026 adjusted ebitda
- 385000000
- Operating cash flow q4
- 90000000
- Adjusted ebitda margin q4
- 24.3%
- Adjusted eps ex intangibles amortization
- 1.12
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.